Major Article - BIT225, in combination with 3-drug antiretroviral therapy, page-197

On what basis do you expect BIT225 to work well?

Very unlikely it was that great, as otherwise you would think they would have announced that when they reported the initial assay results. Furthermore, if it showed exceptional results during the preliminary testing, they could have quickly entered into clinical trials given this compound has already been tested in humans and its safety profile is known.

https://www.biopharmadive.com/news/roche-atea-coronavirus-antiviral-drug-deal/587530/

In other news, Roche paid a lot of money ($350 million) to get their hands on the rights to a new antiviral drug (see link above).

Unfortunately, no one has ever been interested in a single one of BIT's compounds. If BIT225 showed any promise at all, Roche could have paid a lot less than $350 million to get their hands on it. At this point in time, I think MM would probably be happy to give Roche the rights to develop BIT225 for some loose change.